Causal associations between plasma proteins and prostate cancer: a Proteome-Wide Mendelian Randomization

Chen Lin[1 #], Rong Zhuona[1#], Gu Yanlun[1,2], Chen Yuke[3], Yu Wei[3], Zhou Ying[1*], Pang Xiaocong[1*]

[1] Department of Pharmacy, Peking University First Hospital, Xishiku Street, Xicheng District, 100034 Beijing, China

[1,2] School of Pharmaceutical Sciences, Peking University, Xueyuan Road 38, Haidian District, 100191 Beijing, China

[3] Department of Urology Surgery, Peking University Third Hospital, Xueyuan Road 38, Haidian District, 100191 Beijing, China

*Corresponding author.

#Contributed equally.

Abstract

Background:

Due to the limitations in specificity of current diagnostic methods for prostate cancer (PCa), more reliable biomarkers are needed to explore for improving early detection. Plasma proteins represent a promising source of biomarkers, therefore understanding the causal relationships between specific plasma proteins and PCa could be conductive to identify novel biomarkers and therapeutic targets for PCa prevention and treatment.

Methods:

We performed a meta-analysis of two independent genome-wide association studies

(GWASs) including 94,397 individuals with PCa and 192,372 controls. A mendelian

randomization (MR) supplemented by colocalization analysis was conducted, using

cis-acting variants on 4,907 plasma proteins from deCODE Genetics (N=35,559) and

2,940 plasma proteins from UK Biobank Pharma Proteomics Project (UKB-PPP)

(N=54,219). Then, the biological pathway analysis and druggability evaluation of the

risk proteins were further performed.

Results:

Five possible susceptibility loci (JAZF1, PDILM5, WDPCP, EEFSEC, and TNS3) for

PCa were identified through the meta-analysis of GWASs. Among 3,722 plasma

proteins, 193 proteins were associated with PCa risk, of which 20 high-risk proteins,

including KLK3, were validated in both the deCODE and UKB-PPP cohorts.

Functional annotation of these genes encoding proteins confirmed enrichment of

immune response, inflammatory response, cell-cell interaction and so on. Genetic

colocalization and druggable genome analyses also identified several potential drug

targets for PCa, such as HSPB1, RRM2B and PSCA.

Conclusions:

We identified novel variants as well as several protein biomarkers linked to PCa risk

and indicated pathways associated with PCa, which offered new insights into PCa

etiology and contributed to development of novel biomarkers for early detection and

potential therapeutic interventions.

Funding:

This work was supported by grants from Beijing Municipal Natural Science

Foundation (grant No. JQ24059, No. L234038) and National Natural Science

Foundation of China (grant No. 82274015).

Keywords: Prostate cancer, Proteins, Biomarkers, Mendelian randomization,

Colocalization analysis

Graphical abstract: A comprehensive study design summarized as follows.

Introduction

Prostate cancer (PCa) is the second most common malignancy with an estimation of 1.5 million new cases in 2022, which is account for 14% of total cancer diagnosed in men worldwide(Ferlay J, 2024). Even more worrying is that the number of new cases of PCa are projected to 2.9 million by 2040(James et al., 2024). Despite advancements in medical technology, early detection of PCa remains a significant challenge due to the limitations in specificity of current diagnostic methods, such as prostate-specific antigen (PSA) testing(Carter et al., 2013; Draisma et al., 2009; Oesterling, 1991). Therefore, there is an urgent need for more accurate and reliable biomarkers that can improve early detection and prognostic evaluations of PCa.

Plasma proteins have key roles in the development and progression of PCa, such as interleukin (IL)-6(Deichaite et al., 2022), insulin-like growth factor (IGF)-1 and IGF-binding protein (IGFBP)-1(Cao et al., 2015). However, observational studies exploring the association between plasma proteins and PCa risk are often limited by confounding factors and selection bias, making it challenging to establish a clear causal relationship.

To overcome these limitations, Mendelian randomization (MR) offers a robust methodological approach. This approach utilizes the principle of random assortment of genes from parents to offspring, using genetic variation as an instrumental variable, which mimics the randomization process in a controlled trial, thereby minimizing the impact of reverse causality(Davies, Holmes, & Smith, 2018). With the recent development of proteomics technology, several large-scale proteomic studies have

identified over 18,000 protein quantitative trait loci (pQTLs) covering more than 4800

proteins(Ferkingstad et al., 2021; Pietzner et al., 2021). By using MR, researchers can

gain a deeper comprehension of whether particular plasma proteins hold a causal

nexus with PCa, thereby potentially unraveling novel biomarkers and targets for the

prevention and treatment of PCa.

In this study, we performed a meta-analysis of two genome-wide association studies

(GWAS) on PCa (PRACTICAL and FinnGen) for a total sample size of 94,397 cases

and 192,372 controls. Based on GWAS summary statistics data from deCODE and

UKB-PPP cohorts, we further performed a protein-wide MR (PW-MR) study,

supplemented by colocalization analysis, to explore the casual relationship between

plasma proteins and PCa risk. Moreover, we indicated biological processes and

pathways associated with PCa, and evaluated the druggability of risk proteins. We

aimed to identify novel plasma proteins biomarkers for PCa, which could address the

limitations of current diagnostic methods and offer new insights into the biological

mechanisms   of   PCa   and   potential   therapeutic   targets   for   intervention.

Results

Meta-analysis of the Genome-Wide Association Studies for Prostate Cancer

We conducted a meta-analysis combing two GWAS studies with a collective sample size of 94,397 individuals with PCa and 192,372 controls, aiming to identify genetic variants linked to PCa. The associations and assessment of SNPs heterogeneity that passed the genome-wide P-value threshold at these loci with PCa were presented in Supplementary Table 1. We found 5 genetic risk loci contained at least one SNP passing the genome-wide significance threshold of $P \leq 5 \times 10^{-8}$: JAZF1, PDILM5, WDPCP, EEFSEC, and TNS3 (Figure 1). Among them, PDLIM5, WDPCP, EEFSEC and TNS3 were promising candidates as novel susceptibility loci associated with PCa. Supplementary Figure 1 displayed the associated quantile-quantile plot. The LocusZoom plots of the top SNPs at JAZF1, PDILM5, WDPCP, EEFSEC and TNS3, along with their genomic location, GWAS P values and recombination rate with neighboring SNPs were visualized in Supplementary Figure 2. In summary, this GWAS meta-analysis discovered genetic variations in one recognized PC-associated loci and four potential novel loci, providing a reliable dataset for MR analyses.

Cross-phenotype Analysis of Prostate Cancer

We used the iCPAGdb to conduct the cross-phenotype genetic association analyses with PCa genome-wide significant SNPs ($P \leq 5 \times 10^{-8}$). The iCPAGdb offered an improved algorithm for identifying cross-phenotype associations by using pre-computed ancestry-specific LD databases and integrating genetic data from 3793 traits in the NHGRI-EBI GWAS catalog(L. Wang et al., 2020). After adjusting for

Bonferroni's correction, the cross-phenotype analysis indicated that 117 traits showed

significant association with PCa (Supplementary Table 2). As shown in Figure 2, the

top 10 enrichments were for prostate specific antigen measurement ($P=7.16\times10^{-43}$),

body height ($P=2.18\times10^{-30}$), BMI-adjusted waist-hip ratio ($P=1.32\times10^{-26}$), high

density lipoprotein cholesterol measurement ($P=2.38\times10^{-22}$), systolic blood pressure

($P=2.93\times10^{-22}$), balding measurement ($P=3.01\times10^{-22}$), leukocyte count ($P=3.46\times10^{-21}$

), blood protein measurement ($P=4.95\times10^{-21}$), body mass index ($P=1.71\times10^{-20}$) and

heel bone mineral density ($P=2.02\times10^{-19}$).

Proteome-Wide Mendelian Randomization Studies of Prostate Cancer

The genetic association summary statistics of 35,559 Icelanders from deCODE

Genetics and 54,219 Europeans from the UKB-PPP were utilized to investigate the

relationship between PCa and plasma proteins. Our genetic instrument selection

strategy enabled us to examine 1778 and 1944 proteins from deCODE and UKB-PPP

(Supplementary Table 3A and B). Using the Wald ratio or IVW method, a total of 193

unique plasma proteins were significantly associated with PCa after multiple tests

with a 5% FDR correction. This analysis yielded 137 proteins in UKB-PPP more than

76 proteins in deCODE (Figure 3A). The results of Heterogeneity test based on Q

statistics showed little evidence of heterogeneity. Furthermore, no significant

intercept was detected, implying that there was no directional pleiotropy observed.

After FDR correction, 20 proteins were detected in both data sets and the identified

associations were consistent (Figure 3B). Genetic prediction indicated that 11 of these

20 proteins were positively associated with the risk of PCa as well as remaining 9

proteins were negatively associated, suggesting that these 9 proteins maybe protective

factors against PCa (Supplementary Table 4). A PhenoGram depicted the

chromosomal location of the 193 unique identified proteins in deCODE and UKB-

PPP studies (Figure 3C).

Colocalization analysis

We performed colocalization analyses of proteins significantly expressed in deCODE

and UKB-PPP studies with PCa. It was observed that 4 proteins in deCODE study and

7 proteins in UKB-PPP were colocalized with PCa associations with high support of

evidence (PPH4 $\geq$ 0.8) (Table 1), suggesting that these 10 plasma proteins might serve

as potential targets for treating PCa. Among them, SERPINA3 showed strong

colocalization evidence in both decode (PPH4=0.952) and UKB-PPP (PPH4=0.951)

studies. This analysis identified 1 causal variant in deCODE (rs61976125) and 1

causal variant in Fenland (rs6575449) (Figure 4).

Table 1. Analysis of Mendelian randomization and colocalization of significant proteins with PCa.

GWAS	Outcomes	Proteins	Mendelian randomization			Colocalization
			OR (95%CI)	P value	P value after FDR adjustment	Analysis PH4
deCODE	Prostate Cancer	MSMB	0.86(0.84,0.88)	1.56E-27	2.82E-24	0.999
		POGLUT3	0.89(0.83,0.96)	1.16E-03	2.44E-02	0.998
		PRSS3	0.93(0.91,0.94)	1.00E-18	6.03E-16	0.956
		SERPINA3	1.11(1.06,1.15)	7.18E-08	1.05E-05	0.952
UKB-PPP	Prostate Cancer	USP28	0.47(0.40,0.56)	7.27E-17	2.89E-14	0.999
		KLK3	9.70(4.94,19.03)	3.83E-11	6.91E-09	0.999
		IGFBP3	1.07(1.05,1.09)	2.04E-11	4.49E-09	0.997
		CASP10	1.22(1.11,1.34)	4.73E-05	1.54E-03	0.988
		HDGF	0.96(0.95,0.97)	2.61E-17	1.29E-14	0.966
		SERPINA3	1.10(1.07,1.13)	1.64E-10	2.32E-08	0.951
		C5	1.19(1.11,1.27)	5.32E-07	4.06E-05	0.883

145 OR, odds ratio; CI, confidence interval; FDR, false discovery rate.

Gene-Based Association and Pathway Analyses

We used the GENE2FUNC tool available in FUMA to explore the biological significance, functional implications and tissue-specific expression of the genes identified from our GWAS. These genes appeared to be significantly enriched in inflammatory and immune pathways (such as defense, immune and inflammatory response), as well as cell interaction and signaling pathways (such as interaction between organism and cell adhesion) (Figure 5A). The KEGG pathway enrichment analysis revealed several pathways that were significantly enriched, such as cytokine-cytokine receptor interaction, p53 signaling pathway, JAK-STAT signaling pathway, pathways in cancer and apoptosis (Figure 5B). These analyses indicated potential biological processes and mechanisms associated with PCa. The 193 unique genes were predominantly expressed in the lymphocytes, blood, liver and prostate (Supplementary Figure 3).

Druggability of identified proteins

Exploring new therapeutic opportunities for PCa based on genetic information is crucial for developing targeted treatments. In our study, we examined the druggability of genes and proteins identified in MR analyses using OpenTargets databases. We investigated 128 unique drugs targeting 45 identified proteins (Supplementary Table 5). Among these, three drugs (APATORSEN, TRIAPINE and MK-4721) currently in clinical trials were intended for PCa treatment, with each targeting HSPB1, RRM2B and PSCA, respectively. Notably, the effects of these drugs on their respective protein targets align with the directions indicated by our MR results, suggesting a consistency

168   between genetic evidence and therapeutic potential. In addition, several other

169   identified targets, such as RET, FGFR3, NCAM1, TYMP, TNFRSF10B, MMP3,

170   TACSTD2 and NOTCH2, were implicated in various cancers and present potential

171   therapeutic avenues.

Discussion

In this study, we conducted a comprehensive meta-analysis of two GWAS for PCa, identifying significant genetic loci associated with PCa risk. The combined sample size of 94,397 cases and 192,372 controls revealed one known (JAZF1) and four potential novel (PDLIM5, WDPCP, EEFSEC and TNS3) susceptibility loci of PCa. JAZF1 (Juxtaposed with another zinc finger gene 1) is a transcriptional repressor of testicular nuclear receptor 4 (TR4) (Nakajima, Fujino, Nakanishi, Kim, & Jetten, 2004). Several GWAS studies have implicated that JAZF1 is highly associated with type 2 diabetes and PCa risk(Frayling, Colhoun, & Florez, 2008; Machiela et al., 2012; Saxena, Voight, Zeggini, Scott, & Genetics, 2008; Thomas et al., 2008). JAZF1 may influence the risk of PCa through its role in metabolic regulation(Rosario et al., 2023) and cellular proliferation(Sung et al., 2018).

PDLIM5 (PDZ and LIM domain 5) is a member of the enigma subfamily and features a N-terminal PDZ domain and three C-terminal LIM domains(X. J. Wang & Su, 2010). A study implicated that downregulating the expression of PDLIM5 could ultimately impede the progression of PCa(Xie et al., 2020). WDPCP, a PCP effector, can regulate PCP by directly modulating the actin cytoskeleton(Cui et al., 2013). Disruption of PCP signaling can cause abnormal cell behavior and tissue structure, leading to the development of cancer(Humphries & Mlodzik, 2018). EEFSEC (eukaryotic elongation factor, selenocysteine-tRNA specific) was identified as a genome-wide significant loci in recent chronic obstructive pulmonary disease GWAS(Hobbs et al., 2017; Wain et al., 2017). TNS3 (Tensin 3) is involved in cell

migration, invasion and adhesion processes(Chen et al., 2017; Martuszewska et al.,

2009; Zheng et al., 2021; Zuidema et al., 2022), which are critical in cancer

metastasis. To certain whether these 4 genes causative factors for PCa, genetic

association studies with a larger sample size will be needed.

In the cross-phenotype Analysis of PCa, we found that prostate specific antigen (PSA)

measurement, BMI-adjusted waist-hip ratio (WHR), high density lipoprotein

cholesterol (HDL) measurement, systolic blood pressure, balding measurement and

other traits were significantly associated with PCa. These findings highlighted the

multifactorial nature of PCa and underscored the importance of considering a broad

range of physiological and biochemical factors in understanding its etiology and

progression.

PSA measurement, a protein secreted by both normal and malignant prostate epithelial

cells, has long been a cornerstone in the early detection and monitoring of

PCa(Oesterling, 1991). However, the specificity and sensitivity of PSA as a diagnostic

tool have been questioned due to its elevation in benign conditions such as prostatitis

and benign prostatic hyperplasia, leading to unnecessary biopsies(Carter et al., 2013)

and substantial overdiagnosis(Draisma et al., 2009). Therefore, supplementary

biomarkers are urgently needed to improve diagnostic accuracy.

Obesity has emerged as a significant risk factor in cancer development(Petrelli et al.,

2021), such as aggressive PCa(Moyad, 2015). The significant association between

BMI-adjusted WHR and PCa suggested that central obesity may play a critical role in

the development of PCa(Perez-Cornago, Dunneram, Watts, Key, & Travis, 2022).

Central adiposity, primarily referring to visceral adipose tissue, can influence

hormone levels and inflammatory processes, thereby contributing to

carcinogenesis(Doyle, Donohoe, Lysaght, & Reynolds, 2012). HDL cholesterol is

known for its atherosclerotic protective effects(Rohatgi, Westerterp, von Eckardstein,

Remaley, & Rye, 2021), mainly due to the ability to promote the reverse transport of

cholesterol from peripheral cells to the liver for excretion(Cuchel & Rader, 2006), and

to exert antioxidant and anti-inflammatory activities. Through similar mechanisms,

HDL may influence the development and progression of tumors, by directly

interacting with cancer cells or by modifying the tumor microenvironment(Ossoli,

Wolska, Remaley, & Gomaraschi, 2022). Higher HDL levels might confer a

protective effect against PCa by influencing cancer cells proliferation, possibly

through mechanisms involving antioxidant(Ruscica et al., 2018) and anti-

inflammatory properties.

Results from previous studies of the association between hypertension and PCa

development have been inconsistent(Christakoudi et al., 2020; Liang et al., 2016;

Seretis et al., 2019). One MR analysis suggested that elevated systolic blood pressure

might be linked to an increased risk of PCa, potentially due to systemic

inflammation(Stikbakke et al., 2022), which contributed to a pro-tumorigenic

environment by promoting cellular proliferation, DNA damage, and resistance to

apoptosis(Mantovani, Allavena, Sica, & Balkwill, 2008). However, the precise

relationship between systolic blood pressure and PCa remains unclear. More research

is needed to elucidate the exact biological pathways involved and to determine

whether managing hypertension could serve as a preventive strategy for PCa.

The underlying mechanism for the link between androgenic alopecia and an increased

risk of PCa may involve androgen metabolism, as both conditions are influenced by

dihydrotestosterone (DHT) levels. Elevated DHT can promote the miniaturization of

hair follicle leading to balding(Kaufman, 1996), as well as stimulate prostate cell

proliferation(Tong et al., 2022), contributing to the development of PCa. While these

associations highlight a potential shared hormonal pathway, further studies are needed

to confirm the causality. Overall, our cross-phenotype analysis provided a

comprehensive view of the diverse factors associated with PCa and enhanced our

understanding of the disease's multifaceted nature. Future researches should focus on

elucidating the underlying mechanisms of these associations and exploring their

potential for integration into clinical practice.

We performed a PW-MR study supplemented by colocalization analysis to explore the

casual association of 3,722 plasma proteins with the risk of PCa. MR analysis

identified a total of 193 unique proteins significantly associated with PCa, of which

10 proteins had a strong support of colocalization. Microseminoprotein-beta

(MSMB), also known as PSP94 or beta-inhibin, as an immunoglobulin superfamily

protein and one of the most abundant proteins secreted by prostate epithelial cells has

the strongest correlation(Byrne et al., 2019). We predicted that men with lower blood

levels of MSMB have higher risk of PCa, based on two European ancestry cancer

GWAS studies. These results were consistent with another published prospective

study(Haiman et al., 2013), supporting a potential protective role of MSMB in the

development of PCa. One previous publication reported that the decreased expression

of MSMB was both in the tumor (especially in more advanced tumor) and adjacent

benign prostate tissue(Bergström, Järemo, Nilsson, Adamo, & Bergh, 2018), which is

not in conflict as it may be related to aggressiveness of prostate tumors. Although the

mechanism of action of MSMB in PCa is unclear, it has been shown to control

prostate cell growth by regulating apoptosis(Garde et al., 1999). In addition to our

study, several other studies also supported the potential of MSMB as a serum marker

for the early detection of PCa(Nam et al., 2006; Reeves, Dulude, Panchal, Daigneault,

& Ramnani, 2006). Consequently, further research is essential to explore the

functional role and possible clinical utility of MSMB in PCa.

Serine protease inhibitor A3 (SERPINA3), an inhibitors of serine proteases that

promotes tumor development by regulating the transcription of some oncogenes and

its elevation was associated with a worse prognosis in some cancers(De Mezer et al.,

2023). SERPINA3 was up-regulated in PCa cells and enhanced cells migration and

invasion(Z. S. Xing, Li, Liu, Zhang, & Bai, 2021), which was consistent with our

prediction of it as a risk factor in this MR Study. A study identified that the enhanced

expression of SERPINA3 stimulated the bone environment, therefore it may be served

as a diagnostic biomarker to predict PCa with bone metastasis phenotype and

survival(Ito et al., 2023).

Protease serine 3 (PRSS3), also named mesotrypsin, is reported to be aberrantly

expressed in various types of tumors and participates in the progression and

development of cancers. For example, PRSS3 was identified to be downregulated in

lung cancer(Zhou, Li, & Luo, 2023) but upregulated in pancreatic cancer(Jiang et al.,

2010; C. J. Xing et al., 2019), suggesting it may have different roles depending on the

cellular or disease ways. A study of *vivo* and *vitro* experiments has demonstrated that

PRSS3 played an important role in PCa metastasis(Hockla et al., 2012). Despite these

findings, further studies are necessary to fully understand the functions and

mechanisms of PRSS3 in human PCa.

KLK3 (Kallikrein Related Peptidase 3), also known as PSA, is a serine protease

predominantly expressed in the prostate gland. One potential mechanism through

which KLK3 may influence PCa development involved its proteolytic activity, which

can degrade extracellular matrix components and facilitate tumor invasion and

metastasis(Avgeris, Mavridis, & Scorilas, 2012; Lawrence, Lai, & Clements, 2010;

Mavridis, Avgeris, & Scorilas, 2014). Additionally, the androgen regulation of KLK3

expression correlated with the androgen receptor signaling pathway, a critical driver

of PCa progression, particularly in castration-resistant prostate cancer (CRPC)(Lilja,

Ulmert, & Vickers, 2008). Despite these insights, the precise biological pathways

through which KLK3 contributes to PCa progression remain incompletely understood.

Further research is needed to illustrate the direct and indirect effects of KLK3 on PCa

cells and the tumor microenvironment.

Lastly, the druggability evaluation identified 45 protein biomarkers that have been

targeted by 128 drugs. Among these, three drugs targeting HSPB1, RRM2B and

PSCA, respectively, are currently in clinical trials for potential use in PCa treatment.

HSPB1, also known as human HSP27, is a small heat-shock protein that functions as

a molecular chaperone, protecting cells against stress-induced damage and apoptosis(Okuno, Adachi, Kozawa, Shimizu, & Yasuda, 2016). It was overexpressed in various cancers(Sheng et al., 2017; Shi et al., 2019), including PCa(Shiota et al., 2013; Vasiljevic et al., 2013), and was associated with tumor progression, metastasis and resistance to therapy. Evidences in *vitro* and in *vivo* suggested that inhibiting HSP27 inhibits tumor growth and sensitivity to cytotoxic chemotherapy(Hadaschik et al., 2008; Kamada et al., 2007). APATORSEN is an antisense oligonucleotide designed to inhibit HSPB1 expression(Jansen & Zangemeister-Wittke, 2002), which is still in clinical trials.

RRM2B is a subunit of ribonucleotide reductase, an enzyme critical for DNA synthesis and repair(Okumura et al., 2005). Its expression was upregulated in response to DNA damage and was involved in maintaining genomic stability(Aye, Li, Long, & Weiss, 2015; Foskolou et al., 2017). Elevated levels and distinct mutation signatures of RRM2B have been linked to poor prognosis in several cancers(Iqbal et al., 2021). PSCA is a cell surface glycoprotein highly expressed in high-grade PCa(Gu et al., 2000; Zhigang & Wenlv, 2004) and other solid tumors(Teng et al., 2022), and was involved in cell proliferation, adhesion and survival(Li et al., 2017).

This study possessed several strengths, including the use of the largest collection of plasma protein data (coving more than 4800 proteins), large sample sizes of GWAS studies, a mutual validation across two independent outcome datasets and the use of colocalization analysis to support the MR results. Additionally, our assessment of the human blood proteome relied on two technologies (SOMAmer and Olink), which

were valuable for identifying plasma proteins associated with diseases traits such as

PCa.

Some limitations of our analysis should be acknowledged. Firstly, this investigation

was only confined to Europeans, restricting the applicability of our findings to other

populations. It is crucial for future studies to identify risk proteins in more diverse

populations, especially African ancestry who face a higher risk of PCa. Moreover, our

study concentrated on the proteins available in the MR analysis, which likely led to

the omission of other potential therapeutic targets. Lastly, we utilized proteomic data

from Icelanders whose genetic backgrounds may differ from other European

populations, which might introduce bias. However, this potential bias might be

minimal, as we found that 20 proteins showing significance ($P<0.05$) in both the

deCODE and UKB-PPP studies had consistent associations with PCa.

In conclusion, we conducted a large-scale PW-MR study using the MR and

colocalization analysis to investigate the genetic associations of up to 3,722 unique

proteins with PCa. We revealed the complex genetic architecture of PCa and

identified many new plasma proteins with strong causal associations to PCa. These

findings highlighted the potential biomarkers for early detection and therapeutic

targets, providing a foundation for future research and potential clinical applications.

Methods

Data sources for plasma proteins

We selected *cis*-SNPs associated with plasma proteins as instrumental variables from

two large-scale GWASs in the deCODE Genetics(Ferkingstad et al., 2021) and UKB-

PPP(Sun et al., 2023). Cis-SNPs were defined as SNPs within a vicinity of ±1 Mb

around the gene encoding the protein. From these SNPs, only those with a minor

allele frequency of ≥ 1% that were genome-wide significance ($p < 5 \times 10^{-8}$) and

considered independent (linkage disequilibrium $r^2 < 0.1$ in 1000G) were retained.

deCODE Genetics conducted proteomic profiling on blood plasma samples from

35,559 Icelanders using the SomaScan platform and collected data on 4907

aptamers(Ferkingstad et al., 2021). For the two-sample MR analysis, we selected cis-

SNPs as instrumental variables for 1778 proteins. Likewise, cis-SNPs for 1944

plasma proteins were obtained from the UKB-PPP where 2940 proteins were

measured among 54,219 Europeans using the Olink platform(Sun et al., 2023). The

proteins with positive MR results were included in the colocalization analysis.

Data sources for Prostate Cancer

GWAS summary statistics for PCa were obtained from the PRACTICAL

consortium(Schumacher et al., 2018) and FinnGen study. The PRACTICAL (Prostate

Cancer Association Group to Investigate Cancer Associated Alterations in the

Genome) consortium included 79,198 cases and 61,106 controls. We used the data on

PCa from the FinnGen study R10 in this analysis, which comprised 15,199 cases and

131,266 controls. All participants of these two cohorts were of European ancestry. In

the MR analysis, we treated the PRACTICAL consortium as the discovery study and

the FinnGen R10 study as the replication. To increase the effectiveness, we performed

a fixed-effect GWAS meta-analysis of the two GWASs using the METAL package.

The quantile-quantile plot was generated using the "qqman" package in R software.

The R package "gassocplot" was used to plot regional association plots for the top

SNP at each of the genome-wide significant loci identified.

Cross-phenotype analysis

Through the interactive Cross-Phenotype Analysis of GWAS database (iCPAGdb)(L.

Wang et al., 2020), a new platform for cross-phenotype analysis, we explored the

genetic correlation between PCa and other traits. We analyzed the genetic correlations

between PCa and 3793 traits using data from the National Human Genome Research

Institute-European Bioinformatics Institute (NHGRI-EBI) GWAS catalog(L. Wang et

al., 2020). Through the use of ancestry LD-specific association data, iCPAGdb

performs cross-phenotype enrichment analyses. iCPAGdb reveals signals of pairwise

traits and shared signals by analyzing traits associations with LD proxy SNPs. The

output data will show results from Fisher's exact test with adjustment for 5% false

discovery rate (FDR) and also Bonferroni's, Jaccard's, Sorensen's, and Chao-

Sorensen similarity indexes.

MR analysis

We conducted a MR analysis with plasma proteins as the exposure variable and PC as

the outcome variable. We utilized the R package "TwoSampleMR" in R software

(4.3.3) for the MR analysis. When only one SNP was available for a particular

protein, we applied the Wald ratio test. Inverse-variance weighted (IVW) was used as

the main analysis method for two or more SNPs available. Considering multiple

testing, we employed the 5% False Discovery Rate (FDR) method for P-value

correction. P<0.05 was considered statistically significant. MR-Egger and weighted

median methods were used as supplementary analysis methods. Cochran's Q statistic

test using the MR-Egger method was used to determine the heterogeneity between the

genetic variants. We also performed MR-Egger regression intercept to detect and

adjust the directional horizontal pleiotropy(Hemani, Bowden, & Smith, 2018), P<0.05

was considered as the presence of directional pleiotropy and thus removed from the

further analyses.

Colocalization analysis

The "coloc" package was used to perform Bayesian colocalization analysis to

investigate if the associations between plasma proteins and PCa were driven by

linkage disequilibrium (LD) (Giambartolomei et al., 2014). For proteins with positive

MR results, the Bayesian method assessed the support for the following five exclusive

hypotheses: 1) no association with either trait; 2) association with trait 1 only; 3)

association with trait 2 only; 4) both traits are associated, but distinct causal variants

were for two traits; and 5) both traits are associated, and the same shares causal

variant for both traits(Foley et al., 2021). The posterior probability is provided for

each hypothesis (H0, H1, H2, H3, and H4). In this analysis, we set prior probabilities

of the SNP being associated with trait 1 only (p1) at 1×10^{-4}; the probability of the

SNP being associated with trait 2 only (p2) at 1×10^{-4}; and the probability of the SNP

being associated with both traits (p12) at 1×10^{-5}. Two signals were considered to

have strong evidence of colocalization if the posterior probability for shared causal

variants (PH4) was ≥0.8. The analysis was performed in R software (4.3.3).

Biological pathway analysis

The GENE2FUNC tool in FUMA(Watanabe, Taskesen, van Bochoven, & Posthuma,

2017) web application programming interface version 1.5.2 were used to investigate

functional annotation and enrichment analysis of the genes coding for the 193 unique

proteins identified by the PW-MR approach. This analysis involved calculating the

log2 fold-change expression for each gene across 54 tissue types from the GTEx

(Genotype-Tissue Expression) database. We conducted gene enrichment analysis to

identify overrepresented biological processes using the Gene Ontology (GO)

database, which helped determine the biological processes most relevant to the genes

identified. To investigate the involvement of the identified genes in functional and

signaling pathways, we used the KEGG (Kyoto Encyclopedia of Genes and Genomes)

pathway database. Enrichment results were considered significant if they passed 5%

FDR P-value threshold. Additionally, only enrichments involving at least two

overlapping genes with the gene sets were considered to ensure robustness and

biological relevance.

Druggability evaluation

The analysis of drug targets for the significant proteins identified in the MR Analysis

was conducted using data from OpenTargets(Ochoa et al., 2023) (v.22.11), which is

publicly accessible. We selected all drugs for which there was evidence for an

association with the protein of interest.

Data availability

The GWAS summary statistics of blood pQTLs from deCODE can be found at https://www.decode.com/summarydata/, and those of the UKB-PPP can be found at https://www.synapse.org/#!Synapse:syn51365303. Summary statistics of PCa from the PRACTICAL consortium can be obtained from OpenGWAS (https://gwas.mrcieu.ac.uk/), and those of the FinnGen study can be obtained from https://r10.finngen.fi/. The OpenTargets data were downloaded directly from the OpenTargets website (https://platform.opentargets.org/downloads/data).

Acknowledgements

The authors would like to thank all the participants and investigators of the studies (PRACTICAL, FinnGen, deCODE, UKB-PPP) for providing the invaluable data used in this research. Their commitment and effort have been essential for the success of this study. Furthermore, special thanks to our colleagues and collaborators for their insightful discussions and feedback throughout the research process. This research was funded by Beijing Municipal Natural Science Foundation (grant No. JQ24059, No. L234038), and National Natural Science Foundation of China (grant No. 82274015).

References

Avgeris, M., Mavridis, K., & Scorilas, A. (2012). Kallikrein-related peptidases in prostate, breast, and ovarian cancers: from pathobiology to clinical relevance. *Biol Chem, 393*(5), 301-317. doi:10.1515/hsz-2011-0260

Aye, Y., Li, M., Long, M. J. C., & Weiss, R. S. (2015). Ribonucleotide reductase and cancer: biological mechanisms and targeted therapies. *Oncogene, 34*(16), 2011-2021. doi:10.1038/onc.2014.155

Bergström, S. H., Järemo, H., Nilsson, M., Adamo, H. H., & Bergh, A. (2018). Prostate tumors downregulate microseminoprotein-beta (MSMB) in the surrounding benign prostate epithelium and this response is associated with tumor aggressiveness. *Prostate, 78*(4), 257-265. doi:10.1002/pros.23466

Byrne, K. S., Appleby, P. N., Key, T. J., Holmes, M. V., Fensom, G. K., Agudo, A., . . . Consortium, P. (2019). The role of plasma microseminoprotein-beta in prostate cancer: an observational nested case-control and Mendelian randomization study in the European prospective investigation into cancer and nutrition. *Annals of Oncology, 30*(6), 983-989. doi:10.1093/annonc/mdz121

Cao, Y., Nimptsch, K., Shui, I. M., Platz, E. A., Wu, K., Pollak, M. N., . . . Giovannucci, E. L. (2015). Prediagnostic plasma IGFBP-1, IGF-1 and risk of prostate cancer. *International Journal of Cancer, 136*(10), 2418-2426. doi:10.1002/ijc.29295

Carter, H. B., Albertsen, P. C., Barry, M. J., Etzioni, R., Freedland, S. J., Greene, K. L., . . . Zietman, A. L. (2013). Early Detection of Prostate Cancer: AUA Guideline. *Journal of Urology, 190*(2), 419-426. doi:10.1016/j.juro.2013.04.119

Chen, H. Y., Lin, L. T., Wang, M. L., Laurent, B., Hsu, C. H., Pan, C. M., . . . Chiou, S. H. (2017). Musashi-1 Enhances Glioblastoma Cell Migration and Cytoskeletal Dynamics through Translational Inhibition of Tensin3. *Scientific Reports, 7*, 14. doi:10.1038/s41598-017-09504-7

Christakoudi, S., Kakourou, A., Markozannes, G., Tzoulaki, I., Weiderpass, E.,

Brennan, P., . . . Tsilidis, K. K. (2020). Blood pressure and risk of cancer in the European Prospective Investigation into Cancer and Nutrition. *Int J Cancer, 146*(10), 2680-2693. doi:10.1002/ijc.32576

Cuchel, M., & Rader, D. J. (2006). Macrophage reverse cholesterol transport: key to the regression of atherosclerosis? *Circulation, 113*(21), 2548-2555. doi:10.1161/circulationaha.104.475715

Cui, C., Chatterjee, B., Lozito, T. P., Zhang, Z., Francis, R. J., Yagi, H., . . . Lo, C. W. (2013). Wdpcp, a PCP Protein Required for Ciliogenesis, Regulates Directional Cell Migration and Cell Polarity by Direct Modulation of the Actin Cytoskeleton. *Plos Biology, 11*(11), 17. doi:10.1371/journal.pbio.1001720

Davies, N. M., Holmes, M. V., & Smith, G. D. (2018). Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. *Bmj-British Medical Journal, 362*, 11. doi:10.1136/bmj.k601

De Mezer, M., Rogalinski, J., Przewozny, S., Chojnicki, M., Niepolski, L., Sobieska, M., & Przystanska, A. (2023). SERPINA3: Stimulator or Inhibitor of Pathological Changes. *Biomedicines, 11*(1), 15. doi:10.3390/biomedicines11010156

Deichaite, I., Sears, T. J., Sutton, L., Rebibo, D., Morgan, K., Nelson, T., . . . Carter, H. (2022). Differential regulation of TNFα and IL-6 expression contributes to immune evasion in prostate cancer. *Journal of Translational Medicine, 20*(1), 16. doi:10.1186/s12967-022-03731-x

Doyle, S. L., Donohoe, C. L., Lysaght, J., & Reynolds, J. V. (2012). Visceral obesity, metabolic syndrome, insulin resistance and cancer. *Proc Nutr Soc, 71*(1), 181-189. doi:10.1017/s002966511100320x

Draisma, G., Etzioni, R., Tsodikov, A., Mariotto, A., Wever, E., Gulati, R., . . . de Koning, H. (2009). Lead Time and Overdiagnosis in Prostate-Specific Antigen Screening: Importance of Methods and Context. *Jnci-Journal of the National Cancer Institute, 101*(6), 374-383. doi:10.1093/jnci/djp001

Ferkingstad, E., Sulem, P., Atlason, B. A., Sveinbjornsson, G., Magnusson, M. I., Styrmisdottir, E. L., . . . Stefansson, K. (2021). Large-scale integration of the

plasma proteome with genetics and disease. *Nature Genetics, 53*(12), 1712-+. doi:10.1038/s41588-021-00978-w

Ferlay J, E. M., Lam F, Laversanne M, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F . (2024). Global Cancer Observatory: Cancer Today. Retrieved from https://gco.iarc.who.int/today

Foley, C. N., Staley, J. R., Breen, P. G., Sun, B. B., Kirk, P. D. W., Burgess, S., & Howson, J. M. M. (2021). A fast and efficient colocalization algorithm for identifying shared genetic risk factors across multiple traits. *Nature Communications, 12*(1), 18. doi:10.1038/s41467-020-20885-8

Foskolou, I. P., Jorgensen, C., Leszczynska, K. B., Olcina, M. M., Tarhonskaya, H., Haisma, B., . . . Hammond, E. M. (2017). Ribonucleotide Reductase Requires Subunit Switching in Hypoxia to Maintain DNA Replication. *Molecular Cell, 66*(2), 206-+. doi:10.1016/j.molcel.2017.03.005

Frayling, T. M., Colhoun, H., & Florez, J. C. (2008). A genetic link between type 2 diabetes and prostate cancer - Commentary. *Diabetologia, 51*(10), 1757-1760. doi:10.1007/s00125-008-1114-9

Garde, S. V., Basrur, V. S., Li, L., Finkelman, M. A., Krishan, A., Wellham, L., . . . Tang, D. G. (1999). Prostate secretory protein (PSP94) suppresses the growth of androgen-independent prostate cancer cell line (PC3) and xenografts by inducing apoptosis. *Prostate, 38*(2), 118-125. doi:10.1002/(sici)1097-0045(19990201)38:2<118::Aid-pros5>3.0.Co;2-g

Giambartolomei, C., Vukcevic, D., Schadt, E. E., Franke, L., Hingorani, A. D., Wallace, C., & Plagnol, V. (2014). Bayesian Test for Colocalisation between Pairs of Genetic Association Studies Using Summary Statistics. *Plos Genetics, 10*(5), 15. doi:10.1371/journal.pgen.1004383

Gu, Z., Thomas, G., Yamashiro, J., Shintaku, I. P., Dorey, F., Raitano, A., . . . Reiter, R. E. (2000). Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer. *Oncogene, 19*(10), 1288-1296. doi:10.1038/sj.onc.1203426

Hadaschik, B. A., Jackson, J., Fazli, L., Zoubeidi, A., Burt, H. M., Gleave, M. E., &

So, A. I. (2008). Intravesically administered antisense oligonucleotides targeting heat-shock protein-27 inhibit the growth of non-muscle-invasive bladder cancer. *Bju International, 102*(5), 610-616. doi:10.1111/j.1464-410X.2008.07669.x

Haiman, C. A., Stram, D. O., Vickers, A. J., Wilkens, L. R., Braun, K., Valtonen-André, C., . . . Lilja, H. (2013). Levels of Beta-Microseminoprotein in Blood and Risk of Prostate Cancer in Multiple Populations. *Jnci-Journal of the National Cancer Institute, 105*(3), 237-243. doi:10.1093/jnci/djs486

Hemani, G., Bowden, J., & Smith, G. D. (2018). Evaluating the potential role of pleiotropy in Mendelian randomization studies. *Human Molecular Genetics, 27*(R2), R195-R208. doi:10.1093/hmg/ddy163

Hobbs, B. D., de Jong, K., Lamontagne, M., Bossé, Y., Shrine, N., Artigas, M. S., . . . Int, C. G. C. (2017). Genetic loci associated with chronic obstructive pulmonary disease overlap with loci for lung function and pulmonary fibrosis. *Nature Genetics, 49*(3), 426-432. doi:10.1038/ng.3752

Hockla, A., Miller, E., Salameh, M. A., Copland, J. A., Radisky, D. C., & Radisky, E. S. (2012). PRSS3/Mesotrypsin Is a Therapeutic Target for Metastatic Prostate Cancer. *Molecular Cancer Research, 10*(12), 1555-1566. doi:10.1158/1541-7786.Mcr-12-0314

Humphries, A. C., & Mlodzik, M. (2018). From instruction to output: Wnt/PCP signaling in development and cancer. *Current Opinion in Cell Biology, 51*, 110-116. doi:10.1016/j.ceb.2017.12.005

Iqbal, W., Demidova, E. V., Serrao, S., ValizadehAslani, T., Rosen, G., & Arora, S. (2021). RRM2B Is Frequently Amplified Across Multiple Tumor Types: Implications for DNA Repair, Cellular Survival, and Cancer Therapy. *Frontiers in Genetics, 12*, 13. doi:10.3389/fgene.2021.628758

Ito, K., Yamamoto, T., Hayashi, Y., Sato, S., Nakayama, J., Urabe, F., . . . Yamamoto, Y. (2023). Osteoblast-derived extracellular vesicles exert osteoblastic and tumor-suppressive functions via SERPINA3 and LCN2 in prostate cancer. *Molecular Oncology, 17*(10), 2147-2167. doi:10.1002/1878-0261.13484

James, N. D., Tannock, I., N'Dow, J., Feng, F., Gillessen, S., Ali, S. A., . . . Xie, L.-P. (2024). The Lancet Commission on prostate cancer: planning for the surge in cases. *Lancet (London, England), 403*(10437), 1683-1722. doi:10.1016/s0140-6736(24)00651-2

Jansen, B., & Zangemeister-Wittke, U. (2002). Antisense therapy for cancer - the time of truth. *Lancet Oncology, 3*(11), 672-683. doi:10.1016/s1470-2045(02)00903-8

Jiang, G. Z., Cao, F. Y., Ren, G. P., Gao, D. L., Bhakta, V., Zhang, Y. H., . . . Wang, Y. H. (2010). PRSS3 promotes tumour growth and metastasis of human pancreatic cancer. *Gut, 59*(11), 1535-1544. doi:10.1136/gut.2009.200105

Kamada, M., So, A., Muramaki, M., Rocchi, P., Beraldi, E., & Gleave, M. (2007). Hsp27 knockdown using nucleotide-based therapies inhibit tumor growth and enhance chemotherapy in human bladder cancer cells. *Molecular Cancer Therapeutics, 6*(1), 299-308. doi:10.1158/1535-7163.Mct-06-0417

Kaufman, K. D. (1996). Androgen metabolism as it affects hair growth in androgenetic alopecia. *Dermatol Clin, 14*(4), 697-711. doi:10.1016/s0733-8635(05)70396-x

Lawrence, M. G., Lai, J., & Clements, J. A. (2010). Kallikreins on steroids: structure, function, and hormonal regulation of prostate-specific antigen and the extended kallikrein locus. *Endocr Rev, 31*(4), 407-446. doi:10.1210/er.2009-0034

Li, E. M., Liu, L. H., Li, F. T., Luo, L. M., Zhao, S. K., Wang, J. M., . . . Zhao, Z. G. (2017). PSCA promotes prostate cancer proliferation and cell-cycle progression by up-regulating c-Myc. *Prostate, 77*(16), 1563-1572. doi:10.1002/pros.23432

Liang, Z., Xie, B., Li, J., Wang, X., Wang, S., Meng, S., . . . Xie, L. (2016). Hypertension and risk of prostate cancer: a systematic review and meta-analysis. *Scientific Reports, 6*, 31358. doi:10.1038/srep31358

Lilja, H., Ulmert, D., & Vickers, A. J. (2008). Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. *Nat Rev Cancer, 8*(4), 268-278.

doi:10.1038/nrc2351

Machiela, M. J., Lindström, S., Allen, N. E., Haiman, C. A., Albanes, D., Barricarte,

A., . . . Kraft, P. (2012). Association of Type 2 Diabetes Susceptibility Variants

With Advanced Prostate Cancer Risk in the Breast and Prostate Cancer Cohort

Consortium. *American Journal of Epidemiology, 176*(12), 1121-1129.

doi:10.1093/aje/kws191

Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008). Cancer-related

inflammation. *Nature, 454*(7203), 436-444. doi:10.1038/nature07205

Martuszewska, D., Ljungberg, B., Johansson, M., Landberg, G., Oslakovic, C.,

Dahlbäck, B., & Hafizi, S. (2009). Tensin3 Is a Negative Regulator of Cell

Migration and All Four Tensin Family Members Are Downregulated in

Human Kidney Cancer. *Plos One, 4*(2), 13. doi:10.1371/journal.pone.0004350

Mavridis, K., Avgeris, M., & Scorilas, A. (2014). Targeting kallikrein-related

peptidases in prostate cancer. *Expert Opin Ther Targets, 18*(4), 365-383.

doi:10.1517/14728222.2014.880693

Moyad, M. A. (2015). Preventing aggressive prostate cancer with proven

cardiovascular disease preventive methods. *Asian J Androl, 17*(6), 874-877;

discussion 876. doi:10.4103/1008-682x.156854

Nakajima, T., Fujino, S., Nakanishi, G., Kim, Y. S., & Jetten, A. M. (2004). TIP27: a

novel repressor of the nuclear orphan receptor TAK1/TR4. *Nucleic Acids*

Research, 32(14), 4194-4204. doi:10.1093/nar/gkh741

Nam, R. K., Reeves, J. R., Toi, A., Dulude, H., Trachtenberg, J., Emami, M., . . .

Narod, S. A. (2006). A novel serum marker, total prostate secretory protein of

94 amino acids, improves prostate cancer detection and helps identify high

grade cancers at diagnosis. *Journal of Urology, 175*(4), 1291-1297.

doi:10.1016/s0022-5347(05)00695-6

Ochoa, D., Hercules, A., Carmona, M., Suveges, D., Baker, J., Malangone, C., . . .

McDonagh, E. (2023). The next-generation Open Targets Platform:

reimagined, redesigned, rebuilt. *Nucleic Acids Research, 51*(D1), D1353-

D1359. doi:10.1093/nar/gkac1046

Oesterling, J. E. (1991). PROSTATE SPECIFIC ANTIGEN - A CRITICAL-
ASSESSMENT OF THE MOST USEFUL TUMOR-MARKER FOR
ADENOCARCINOMA OF THE PROSTATE. *Journal of Urology, 145*(5),
907-923. doi:10.1016/s0022-5347(17)38491-4

Okumura, H., Natsugoe, S., Matsumoto, M., Mataki, Y., Takatori, H., Ishigami, S., . . .
Aikou, T. (2005). The predictive value of p53, p53R2, and p21 for the effect of
chemoradiation therapy on oesophageal squamous cell carcinoma. *British
Journal of Cancer, 92*(2), 284-289. doi:10.1038/sj.bjc.6602322

Okuno, M., Adachi, S., Kozawa, O., Shimizu, M., & Yasuda, I. (2016). The Clinical
Significance of Phosphorylated Heat Shock Protein 27 (HSPB1) in Pancreatic
Cancer. *International Journal of Molecular Sciences, 17*(1), 7.
doi:10.3390/ijms17010137

Ossoli, A., Wolska, A., Remaley, A. T., & Gomaraschi, M. (2022). High-density
lipoproteins: A promising tool against cancer. *Biochim Biophys Acta Mol Cell
Biol Lipids, 1867*(1), 159068. doi:10.1016/j.bbalip.2021.159068

Perez-Cornago, A., Dunneram, Y., Watts, E. L., Key, T. J., & Travis, R. C. (2022).
Adiposity and risk of prostate cancer death: a prospective analysis in UK
Biobank and meta-analysis of published studies. *Bmc Medicine, 20*(1), 13.
doi:10.1186/s12916-022-02336-x

Petrelli, F., Cortellini, A., Indini, A., Tomasello, G., Ghidini, M., Nigro, O., . . .
Zaniboni, A. (2021). Association of Obesity With Survival Outcomes in
Patients With Cancer A Systematic Review and Meta-analysis. *Jama Network
Open, 4*(3), 30. doi:10.1001/jamanetworkopen.2021.3520

Pietzner, M., Wheeler, E., Carrasco-Zanini, J., Cortes, A., Koprulu, M., Wörheide, M.
A., . . . Langenberg, C. (2021). Mapping the proteo-genomic convergence of
human diseases. *Science, 374*(6569), 839-+. doi:10.1126/science.abj1541

Reeves, J. R., Dulude, H., Panchal, C., Daigneault, L., & Ramnani, D. M. (2006).
Prognostic value of prostate secretory protein of 94 amino acids and its
binding protein after radical prostatectomy. *Clinical Cancer Research, 12*(20),
6018-6022. doi:10.1158/1078-0432.Ccr-06-0625

Rohatgi, A., Westerterp, M., von Eckardstein, A., Remaley, A., & Rye, K. A. (2021).

HDL in the 21st Century: A Multifunctional Roadmap for Future HDL

Research. *Circulation, 143*(23), 2293-2309.

doi:10.1161/circulationaha.120.044221

Rosario, S. R., Jacobi, J. J., Long, M. D., Affronti, H. C., Rowsam, A. M., &

Smiraglia, D. J. (2023). JAZF1: A Metabolic Regulator of Sensitivity to a

Polyamine-Targeted Therapy. *Molecular Cancer Research, 21*(1), 24-35.

doi:10.1158/1541-7786.Mcr-22-0316

Ruscica, M., Botta, M., Ferri, N., Giorgio, E., Macchi, C., Franceschini, G., . . .

Gomaraschi, M. (2018). High Density Lipoproteins Inhibit Oxidative Stress-

Induced Prostate Cancer Cell Proliferation. *Scientific Reports, 8*(1), 2236.

doi:10.1038/s41598-018-19568-8

Saxena, R., Voight, B. F., Zeggini, E., Scott, L. J., & Genetics, I. C. D. (2008). Meta-

analysis of genome-wide association data and large-scale replication identifies

several additional susceptibility loci for type 2 diabetes. *Diabetes, 57*, A41-

A41. Retrieved from <Go to ISI>://WOS:000256612000133

Schumacher, F. R., Al Olama, A. A., Berndt, S. I., Benlloch, S., Ahmed, M., Saunders,

E. J., . . . Elucidating Loci Involved, P. (2018). Association analyses of more

than 140,000 men identify 63 new prostate cancer susceptibility loci. *Nature*

Genetics, 51(2), 363-363. doi:10.1038/s41588-018-0330-6

Seretis, A., Cividini, S., Markozannes, G., Tseretopoulou, X., Lopez, D. S., Ntzani, E.

E., & Tsilidis, K. K. (2019). Association between blood pressure and risk of

cancer development: a systematic review and meta-analysis of observational

studies. *Scientific Reports, 9*(1), 8565. doi:10.1038/s41598-019-45014-4

Sheng, B. W., Qi, C. C., Liu, B., Lin, Y., Fu, T., & Zeng, Q. D. (2017). Increased

HSP27 correlates with malignant biological behavior of non-small cell lung

cancer and predicts patient's survival. *Scientific Reports, 7*, 12.

doi:10.1038/s41598-017-13956-2

Shi, D. B., Ma, R. R., Zhang, H., Hou, F., Guo, X. Y., & Gao, P. (2019). GAGE7B

promotes tumor metastasis and growth via activating the

p38/pMAPKAPK2/pHSP27 pathway in gastric cancer. *Journal of Experimental & Clinical Cancer Research, 38*, 12. doi:10.1186/s13046-019-1125-z

Shiota, M., Bishop, J. L., Nip, K. M., Zardan, A., Takeuchi, A., Cordonnier, T., . . . Zoubeidi, A. (2013). Hsp27 Regulates Epithelial Mesenchymal Transition, Metastasis, and Circulating Tumor Cells in Prostate Cancer. *Cancer Research, 73*(10), 3109-3119. doi:10.1158/0008-5472.Can-12-3979

Stikbakke, E., Schirmer, H., Knutsen, T., Støyten, M., Wilsgaard, T., Giovannucci, E. L., . . . Thune, I. (2022). Systolic and diastolic blood pressure, prostate cancer risk, treatment, and survival. The PROCA-life study. *Cancer Med, 11*(4), 1005-1015. doi:10.1002/cam4.4523

Sun, B. B., Chiou, J., Traylor, M., Benner, C., Hsu, Y. H., Richardson, T. G., . . . Whelan, C. D. (2023). Plasma proteomic associations with genetics and health in the UK Biobank. *Nature, 622*(7982), 329-338. doi:10.1038/s41586-023-06592-6

Sung, Y., Park, S., Park, S. J., Jeong, J., Choi, M., Lee, J., . . . Kim, M. O. (2018). Jazf1 promotes prostate cancer progression by activating JNK/Slug. *Oncotarget, 9*(1), 755-765. doi:10.18632/oncotarget.23146

Teng, K. Y., Mansour, A. G., Zhu, Z., Li, Z. Y., Tian, L., Ma, S. B., . . . Yu, J. H. (2022). Off-the-Shelf Prostate Stem Cell Antigen-Directed Chimeric Antigen Receptor Natural Killer Cell Therapy to Treat Pancreatic Cancer. *Gastroenterology, 162*(4), 1319-1333. doi:10.1053/j.gastro.2021.12.281

Thomas, G., Jacobs, K. B., Yeager, M., Kraft, P., Wacholder, S., Orr, N., . . . Chanock, S. J. (2008). Multiple loci identified in a genome-wide association study of prostate cancer. *Nature Genetics, 40*(3), 310-315. doi:10.1038/ng.91

Tong, Y., Guo, Y. J., Zhang, Q., Bi, H. X., Kai, K., & Zhou, R. Y. (2022). Combined treatment with dihydrotestosterone and lipopolysaccharide modulates prostate homeostasis by upregulating TNF-α from M1 macrophages and promotes proliferation of prostate stromal cells. *Asian J Androl, 24*(5), 513-520. doi:10.4103/aja2021114

Vasiljevic, N., Ahmad, A. S., Beesley, C., Thorat, M. A., Fisher, G., Berney, D.
M., . . . Lorincz, A. T. (2013). Association between DNA methylation of
<i>HSPB1</i> and death in low Gleason score prostate cancer. *Prostate*
Cancer and Prostatic Diseases, 16(1), 35-40. doi:10.1038/pcan.2012.47

Wain, L. V., Shrine, N., Artigas, M. S., Erzurumluoglu, A. M., Noyvert, B., Bossini-
Castillo, L., . . . Geisinger-Regeneron Discov, E. H. R. (2017). Genome-wide
association analyses for lung function and chronic obstructive pulmonary
disease identify new loci and potential druggable targets. *Nature Genetics,*
49(3), 416-425. doi:10.1038/ng.3787

Wang, L., Balmat, T. J., Antonia, A. L., Constantine, F. J., Henao, R., Burke, T.
W., . . . Ko, D. C. (2020). An atlas connecting shared genetic architecture of
human diseases and molecular phenotypes provides insight into COVID-19
susceptibility. *medRxiv : the preprint server for health sciences*.
doi:10.1101/2020.12.20.20248572

Wang, X. J., & Su, H. B. (2010). Unraveling Enigma in the Z-Disk. *Circulation*
Research, 107(3), 321-323. doi:10.1161/circresaha.110.225615

Watanabe, K., Taskesen, E., van Bochoven, A., & Posthuma, D. (2017). Functional
mapping and annotation of genetic associations with FUMA. *Nature*
Communications, 8, 11. doi:10.1038/s41467-017-01261-5

Xie, P. B., Liu, M. S., Chen, F., Wu, S. M., Shao, T., Wang, W., . . . Zhou, H. Q.
(2020). Long Non-coding RNA AGAP2-AS1 Silencing Inhibits PDLIM5
Expression Impeding Prostate Cancer Progression<i>via</i>Up-Regulation of
MicroRNA-195-5p. *Frontiers in Genetics, 11*, 13.
doi:10.3389/fgene.2020.01030

Xing, C. J., Ye, H., Wang, W. W., Sun, M. M., Zhang, J. Y., Zhao, Z. H., & Jiang, G.
Z. (2019). Circular RNA ADAM9 facilitates the malignant behaviours of
pancreatic cancer by sponging miR-217 and upregulating PRSS3 expression.
Artificial Cells Nanomedicine and Biotechnology, 47(1), 3920-3928.
doi:10.1080/21691401.2019.1671856

Xing, Z. S., Li, S. L., Liu, Z. X., Zhang, C., & Bai, Z. M. (2021). CircSERPINA3

regulates SERPINA3-mediated apoptosis, autophagy and aerobic glycolysis of
prostate cancer cells by competitively binding to MiR-653-5p and recruiting
BUD13. *Journal of Translational Medicine, 19*(1), 13. doi:10.1186/s12967-
021-03063-2

Zheng, J. Y., Wang, C. Y., Gao, C., Xiao, Q., Huang, C. W., Wu, M., & Li, L. Y.
(2021). MLL3 suppresses tumorigenesis through regulating TNS3 enhancer
activity. *Cell Death & Disease, 12*(4), 13. doi:10.1038/s41419-021-03647-2

Zhigang, Z., & Wenlv, S. (2004). Prostate stem cell antigen (PSCA) expression in
human prostate cancer tissues and its potential role in prostate carcinogenesis
and progression of prostate cancer. *World journal of surgical oncology, 2*, 13.
doi:10.1186/1477-7819-2-13

Zhou, M. Y., Li, K. K., & Luo, K. Q. (2023). Shear Stress Drives the Cleavage
Activation of Protease-Activated Receptor 2 by PRSS3/Mesotrypsin to
Promote Invasion and Metastasis of Circulating Lung Cancer Cells. *Advanced*
Science, 10(25), 21. doi:10.1002/advs.202301059

Zuidema, A., Atherton, P., Kreft, M., Hoekman, L., Bleijerveld, O. B., Nagaraj,
N., . . . Sonnenberg, A. (2022). PEAK1 Y635 phosphorylation regulates cell
migration through association with Tensin3 and integrins. *Journal of Cell*
Biology, 221(8), 18. doi:10.1083/jcb.202108027

Graphical abstract:

Figure 1. Manhattan plot of PCa GWAS meta-analysis. The genetic regions containing top SNPs related to PCa are depicted. The red dashed line signifies the genome-wide significance threshold of 5.0×10^{-8}.

Figure 2. The top 10 significant cross-phenotype associations with PCa at a 5% FDR. The x-axis represents the P value of the correlation. BMI, body mass index.

Figure 3. Result of PW-MR on the associations between plasma proteins and the risk of PCa. (A) Volcano plot of PCa PW-MR study using deCODE (the left side) and UKB-PPP (the right side) cohorts. Annotated proteins passed the 5% FDR IVW P-value threshold. The blue and red colors represent a negative and positive effect, respectively. (B) Venn diagram depicting proteins associated with PCa in deCODE and UKB-PPP. (C) PhenoGram of PCa PW-MR study significant associations. The blue dots and the green dots represent the deCODE and UKB-PPP specific proteins, respectively. The red dot represents both simultaneously.

Figure 4. Colocalization plot of SERPINA3 variants associated with PCa in deCODE and UKB-PPP. Variants are color-coded based on their linkage disequilibrium (LD) with the lead SNP (the variant with the lowest p-value). The lead SNP is highlighted in red. Other variants are colored from blue to yellow, indicating decreasing LD with the lead SNP.

Figure 5. Functional annotation of the genetic architecture of PCa. (A) Biological processes and (B) KEGG pathway analysis of the 193 unique proteins identified in deCODE and UKB-PPP.